FDA Panel Says Johnson & Johnson (JNJ) Data Proves That New Psoriasis Drug Works -Bloomberg
More News related to JNJ
- Notable Analyst Rating Changes 9/5: UL, MON, NAV, HOS Upgraded; ANF, TJX, AMD, NBR Downgraded
- Morgan Stanley Assumes Coverage on Johnson & Johnson (JNJ) with an Overweight
- Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and
- VISTAKON(R) Brings ACUMINDER(TM) to Facebook Users
- First Patient Enrolled in Study Evaluating S.M.A.R.T. (R) Nitinol Self-Expandable Stent System in Leg Disease
More News related to FDA
- Orthofix International (OFIX) Receives FDA 510(k) Approval
- Rosetta Genomics (ROSG) Identifies Potential microRNA Biomarkers in Blood Serum
- BioCryst Pharma (BCRX) Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis
- Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
- GTC Biotherapeutics (GTCB) Granted Priority Review from the FDA
Bloomberg is reporting that an FDA panel is saying data from Johnson & Johnson (NYSE: JNJ) proves that its new psoriasis drug works. The FDA usually takes the advice of the panel, but it doesnt' always have to.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
